ArticleWorld journal of urology2013
Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence.
Article in World journal of urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- The glycobiology of prostate cancer: an update.Oncogene · 2026Review
- Exploring the causal role and mechanism of galanin in glioblastoma: integration of mendelian randomization, network analysis, molecular docking and experimental validation.Frontiers in pharmacology · 2026Article
- A Novel Signature Based on Anoikis Associated with BCR-Free Survival for Prostate Cancer.Biochemical genetics · 2023Article
- Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells.Oncology reports · 2023Article
- Galectin-3 in prostate cancer and heart diseases: a biomarker for these two frightening pathologies?Molecular biology reports · 2023Review
- Gal-3 Protein Expression and Localization in Prostate Tumours.Current oncology (Toronto, Ont.) · 2023Article
- Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor.Frontiers in endocrinology · 2023Review
- Galectin functions in cancer-associated inflammation and thrombosis.Frontiers in cardiovascular medicine · 2023Review
- Galactose specific lectins from prostate tissue with different pathologies: biochemical and cellular studies.Molecular biology reports · 2022Article
- Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels.American journal of cancer research · 2022Article
- Glycosylation Changes in Prostate Cancer Progression.Frontiers in oncology · 2021Review
- Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome.Journal for immunotherapy of cancer · 2020Article
- LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.Frontiers in medicine · 2020Article
- Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.Frontiers in immunology · 2020Article
- Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities.Nature reviews. Urology · 2019Review
- Glycans as Biomarkers in Prostate Cancer.International journal of molecular sciences · 2019Review
- Effect of galectin-3 on vasculogenic mimicry in esophageal cancer cells.Oncology letters · 2018Article
- Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).International journal of molecular medicine · 2018Review
- Overexpression of the galectin-3 during tumor progression in prostate cancer and its clinical implications.International journal of clinical and experimental pathology · 2018Article
- Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGalactin-3 is a cell adhesion molecule involved in tumor progression. Our aim was to examine Gal-3 expression in tumor, benign tissue adjacent to the tumor (adjacent-benign) and benign prostate specimens and correlated it with biochemical recurrence. MATERIALS AND
methodsTissue microarrays were prepared from 83 tumor, 78 adjacent-benign and 75 benign tissues obtained from 83 patients undergoing prostatectomy for clinically localized prostate cancer. Tissues were stained using a Gal-3 antibody and immunohistochemistry. The staining was graded between 0 and 300 depending upon staining intensity and the area of staining. In 37 patients on whom there was follow-up (Mean: 57.8 months; Median: 68 months), staining intensity was correlated with biochemical recurrence.
resultsGal-3 showed both nuclear and cytoplasmic localization in benign, adjacent-benign and tumor tissues. Median Gal-3 staining scores significantly decreased from benign (192.5) to adjacent-benign (148.8 p = 0.007) and to tumor (108.8; p < 0.0001) tissues. In univariate analysis, age (p = 0.028), Gleason sum (p = 0.007), T stage (p = 0.011), seminal vesicle invasion (p = 0.009), pre-operative prostate-specific antigen (p = 0.045) and Gal-3 staining in tumor tissues (0.018) significantly correlated with biochemical recurrence. In multivariate analysis, Gal-3 expression in tumor (p = 0.04), adjacent-benign (p = 0.037) and benign (p = 0.005) tissues significantly correlated with biochemical recurrence. Gal-3 staining in tumor tissues had 91.7 % sensitivity, 64 % specificity and 73 % accuracy in predicting biochemical recurrence.
conclusionsThis is the first study that showed a decreasing gradient of Gal-3 expression in benign, adjacent-benign and tumor tissues. Gal-3 expression may be useful in predicting biochemical recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.